Cross-talk between non-genomic and genomic signalling pathways - Distinct effect profiles of environmental estrogens

Toxicology and Applied Pharmacology

Volumn 245, Issue 2, 2010, Pages 160-170

  Silva, Elisabete ^a   Kabil, Alena ^a   Kortenkamp, Andreas ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Estrogen; Estrogen receptor; MAP kinases; Non genomic signalling; Signalling pathways cross talk; Xenoestrogens

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 1,1,1 TRICHLORO 2 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL)ETHANE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA HEXACHLOROCYCLOHEXANE; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; XENOESTROGEN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

BRCA1 PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DDT; DICHLORODIPHENYL DICHLOROETHYLENE; ENVIRONMENTAL POLLUTANTS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LINDANE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77952891039     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.02.015     Document Type: Article

References (64)

1. Acconcia F., Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006, 238:1-14.
2. Ahmad S., Singh N., Glazer R.I. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol. 1999, 58:425-430.
3. Almeida M., Han L., O'Brien C.A., Kousteni S., Manolagas S.C. Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha. Endocrinology 2006, 147:1986-1996.
4. Altucci L., Addeo R., Cicatiello L., Dauvois S., Parker M.G., Truss M., Beato M., Sica V., Bresciani F., Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324.
5. Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. USA 1994, 91:8517-8521.
6. Bonefeld-Jorgensen E.C., Andersen H.R., Rasmussen T.H., Vinggaard A.M. Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity. Toxicology 2001, 158:141-153.
7. Bulayeva N.N., Watson C.S. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ. Health Perspect. 2004, 112:1481-1487.
8. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15:2174-2183.
9. Caristi S., Galera J.L., Matarese F., Imai M., Caporali S., Cancemi M., Altucci L., Cicatiello L., Teti D., Bresciani F., Weisz A. Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells. Cancer Res. 2001, 61:6360-6366.
10. Castoria G., Barone M.V., Di Domenico M., Bilancio A., Ametrano D., Migliaccio A., Auricchio F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 1999, 18:2500-2510.
11. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., Fiorentino R., Varricchio L., Barone M.V., Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20:6050-6059.
12. Castro-Rivera E., Samudio I., Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 2001, 276:30853-30861.
13. Cheskis B.J. Regulation of cell signalling cascades by steroid hormones. J. Cell. Biochem. 2004, 93:20-27.
14. Coosen R., van Velsen F.L. Effects of the beta-isomer of hexachlorocyclohexane on estrogen-sensitive human mammary tumor cells. Toxicol. Appl. Pharmacol. 1989, 101:310-318.
15. Cui X., Zhang P., Deng W., Oesterreich S., Lu Y., Mills G.B., Lee A.V. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol. 2003, 17:575-588.
16. Diel P., Olff S., Schmidt S., Michna H. Effects of the environmental estrogens bisphenol A, o, p′-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J. Steroid Biochem. Mol. Biol. 2002, 80:61-70.
17. Ding Q., Gros R., Limbird L., Chorazyczewski J., Feldman R.D. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am. J. Physiol. Cell Physiol. 2009, 297(5):C1178-C1187.
18. Efron B., Tibshirani An Introduction to the Bootstrap 1993, Chapman & Hall.
19. El Tanani M.K., Green C.D. Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J. Steroid. Biochem. Mol. Biol. 1997, 60:269-276.
20. Filardo E.J., Quinn J.A., Bland K.I., Frackleton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660.
21. Finn R.S. Targeting Src in breast cancer. Ann. Oncol. 2008, 19:1379-1386.
22. Gaub M.P., Bellard M., Scheuer I., Chambon P., Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990, 63:1267-1276.
23. Hatakeyama M., Matsumura F. Correlation between the activation of Neu tyrosine kinase and promotion of foci formation induced by selected organochlorine compounds in the MCF-7 model system. J. Biochem. Mol. Toxicol. 1999, 13:296-302.
24. Hatakeyama M., Zou E., Matsumura F. Comparison of the characteristic of estrogenic action patterns of beta-HCH and heregulin beta1 in MCF-7 human breast cancer cells. J. Biochem. Mol. Toxicol. 2002, 16:209-219.
25. Ignar-Trowbridge D.M., Pimentel M., Parker M.G., McLachlan J.A., Korach K.S. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996, 137:1735-1744.
26. Improta-Brears T., Whorton A.R., Codazzi F., York J.D., Meyer T., McDonnell D.P. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. USA 1999, 96:4686-4691.
27. Jeffy B.D., Hockings J.K., Kemp M.Q., Morgan S.S., Hager J.A., Beliakoff J., Whitesell L.J., Bowden G.T., Romagnolo D.F. An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 2005, 7:873-882.
28. Jorgensen M., Vendelbo B., Skakkebaek N.E., Leffers H. Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ. Health Perspect. 2000, 108:403-412.
29. Kabil A., Silva E., Kortenkamp A. Src/Erk signalling is implicated in micronucleus formation. Carcinogenesis 2008, 29(10):1862-1868.
30. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
31. Kelce W.R., Stone C.R., Laws S.C., Gray L.E., Kemppainen J.A., Wilson E.M. Persistent DDT metabolite p, p′-DDE is a potent androgen receptor antagonist. Nature 1995, 375:581-5851.
32. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., Roberson P.K., Weinstein R.S., Jilka R.L., Manolagas S.C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
33. Lee H.W., Eghbali-Webb M. Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways. J. Mol. Cell. Cardiol. 1998, 30:1359-1368.
34. Legler J., Zeinstra M., Schuitemaker F., Lanser P.H., Bogerd J., Brouwer A., Vethaak A.D., De Voogt V.P., Murk A.J., van der Burg B. Comparison of in vivo and in vitro reporter gene assays for short-term screening of estrogenic activity. Environ. Sci. Technol. 2002, 36:4410-4415.
35. Li X., Zhang S., Safe S. Activation of kinase pathways in MCF-7 cells by 17beta-estradiol and structurally diverse estrogenic compounds. J. Steroid. Biochem. Mol. Biol. 2006, 98:122-132.
36. Lobenhofer E.K., Huper G., Iglehart J.D., Marks J.R. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000, 11:99-110.
37. Maor S., Papa M.Z., Yarden R.I., Friedman E., Lerenthal Y., Lee S.W., Mayer D., Werner H. Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm. Metab. Res. 2007, 39:179-185.
38. Marks J.R., Huper G., Vaughn J.P., Davis P.L., Norris J., McDonnell D.P., Wiseman R.W., Futreal P.A., Iglehart J.D. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997, 14:115-121.
39. Martin M.B., Franke T.F., Stoica G.E., Chambon P., Katzenellenbogen B.S., Stoica B.A., McLemore M.S., Olivo S.E., Stoica A. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141:4503-4511.
40. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15:1292-1300.
41. Migliaccio A., Di Domenico M., Castoria G., Nanayakkara M., Lombardi M., de Falco A., Bilancio A., Varrichio L., Ciociola A., Auricchio F. Steroid receptor regulation of epidermal growth signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res. 2005, 65(22):10585-10593.
42. Nadal A., Ropero A.B., Laribi O., Maillet M., Fuentes E., Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc. Natl. Acad. Sci. USA 2000, 97:11603-11608.
43. Norman A.W., Mizwicki M.T., Norman D.P.G. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 2004, 3:27-41.
44. O'Lone R., Frith M.C., Karlsson E.K., Hansen U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 2004, 18:1859-1875.
45. O'Malley B.W., McGuire W.L., Middleton P.A. Altered gene expression during differentiation: population changes in hybridizable RNA after stimulation of the chick oviduct with oestrogen. Nature 1968, 218:1249-1251.
46. Ordonez-Moran P., Munoz A. Nuclear receptors genomic and non-genomic effects converge. Cell Cycle 2009, 8:1675-1680.
47. Payne J., Scholze M., Kortenkamp A. Mixtures of four organochlorines enhance human breast cancer cell proliferation. Environ. Health Perspect. 2001, 109:391-397.
48. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
49. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
50. Porter W., Saville B., Hoivik D., Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11:1569-1580.
51. Prossnitz E., Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol. 2009, 308:32-38.
52. Rajapakse N., Silva E., Scholze M., Kortenkamp A. Deviation from additivity with estrogenic mixtures containing 4-nonylphenol and 4-tert-octylphenol detected in the E-SCREEN assay. Environ. Sci. Technol. 2004, 38:6343-6352.
53. Romagnolo D., Annab L.A., Thompson T.E., Risinger J.I., Terry L.A., Barrett J.C., Afshari C.A. Estrogen upregulation of BRCA1 expression with no effect on localization. Mol. Carcinog. 1998, 22:102-109.
54. Ruehlmann D.O., Steinert J.R., Valverde M.A., Jacob R., Mann G.E. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J. 1998, 12:613-619.
55. Silva E., Lopez-Espinosa M.J., Molina-Molina J.M., Fernandez M., Oleo N., Kortenkamp A. Lack of activity of cadmium in in vitro estrogenicity assays. Toxicol. Appl. Pharmacol. 2006, 216:20-28.
56. Silva E., Scholze M., Kortenkamp A. Activity of xenoestrogens at nanomolar concentrations in the E-Screen assay. Environ. Health Perspect. 2007, 115(Suppl 1):91-97.
57. Soto A.M., Sonnenschein C., Chung K.L., Fernandez M.F., Olea N., Serrano F.O. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ. Health Perspect. 1995, 103(Suppl 7):113-122.
58. Steinmetz R., Young P.C., Caperell-Grant A., Gize E.A., Madhukar B.V., Ben Jonathan N., Bigsby R.M. Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells. Cancer Res. 1996, 56:5403-5409.
59. Stoica A., Saceda M., Doraiswamy V.L., Coleman C., Martin M.B. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J. Endocrinol. 2000, 165:371-378.
60. Stoica A., Saceda M., Fakhro A., Joyner M., Martin M.B. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J. Cell. Biochem. 2000, 76:605-614.
61. Villalobos M., Olea N., Brotons J.A., Olea-Serrano M.F., Ruiz de Almodovar J.M., Pedraza V. The E-screen assay: a comparison of different MCF7 cell stocks. Environ. Health Perspect. 1995, 103(9):844-850.
62. Xu C.F., Chambers J.A., Solomon E. Complex regulation of the BRCA1 gene. J. Biol. Chem. 1997, 272:20994-20997.
63. Yee D., Lee A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5:107-115.
64. Zheng A., Kallio A., Harkonen P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 2007, 148:2764-2777.